The first aims to treat Leber congenital amaurosis—a rare condition causing early childhood blindness—by local subretinal injection of an AAV-based CRISPR-Cas9 vector targeting a cryptic exon in the CEP290 gene (EDIT-101, NCT03872479).14 This evidence concerns the gene CEP290 and Leber congenital amaurosis.